Guggenheim raises Merck stock price target to $145 on pipeline outlook

Guggenheim raised its Merck (MRK) price target to $145 from $140 and kept a Buy rating ahead of the Aug. 4 earnings release, updating 2Q26 sales to $16.25B (from $16.27B) and EPS to $0.28 (from $2.07). The model changes reflect the Terns Pharma acquisition and revised product/pipeline outlooks, with the firm also expecting commentary on Keytruda Qlex and Winrevair after J-code implementation on Apr. 1, 2026. The article also cites FDA approval expanding Capvaxive to ages 2–17 at increased risk, plus sell-side target increases from Scotiabank to $155 and BofA to $141, supporting an upside bias into results.

Analysis

The stock setup is less about this quarter’s print and more about whether Merck can keep building credible revenue bridges ahead of the Keytruda overhang. The market usually rewards large-cap pharma only when reimbursement, launch cadence, and late-stage data all line up; if Winrevair and the next wave of pipeline assets show sequential traction, MRK can migrate from a defensive multiple to a growth-franchise multiple over the next 6-18 months.

The near-term catalyst is the Aug. 4 call, but the real price action driver will be whether management sounds confident that newer assets can offset maturity in the core base without relying on aggressive model assumptions. Analyst target bumps matter less than evidence that adoption friction is falling; if that is true, the names most at risk are other oncology-heavy pharmas with weaker pipelines and more exposed earnings quality. If not, the market can quickly reverse from “pipeline optimism” to “terminal growth discount,” especially if upcoming readouts slip or commercial ramp comments are soft.

Contrarian view: consensus may be overpricing the value of incremental approvals and underpricing execution risk. A lot of the visible positives are channel-access or label-expansion items that improve visibility, but they do not by themselves close the gap created by future LOE pressure. The thesis is falsified if Aug. 4 commentary shows slower-than-expected uptake, weaker 2026 revenue cadence, or if any of sac TMT / tulisokibart / MK-3000 lose timing or differentiation versus peer assets.

Key Decisions for Investors

• Add MRK on any earnings-related pullback into the Aug. 4 call; target a 1-3 month rebound of 8-12% if management confirms faster-than-model commercial uptake and no pipeline slippage.
• Pair trade: long MRK / short PFE for a 3-6 month relative-value expression. MRK has the cleaner near-term catalyst path and less balance-sheet/portfolio overhang; thesis breaks if PFE surprises with stronger oncology execution or MRK commentary turns vague.
• Use a limited-risk MRK Sep/Oct call spread rather than naked calls if implied vol is elevated into earnings. This keeps upside participation tied to a catalyst while capping premium burn if the event is a non-event.
• If MRK trades above the post-call reaction high and management raises confidence on 2026-2027 growth bridges, add on confirmation; if the stock fails to hold the post-earnings move or guidance is trimmed, treat that as a signal to reduce exposure rather than averaging down.